大洋生物
(003017)
| 流通市值：22.73亿 | | | 总市值：27.55亿 |
| 流通股本：6928.80万 | | | 总股本：8400.00万 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 442,828,313.51 | 378,284,207.54 | 353,101,246.36 | 353,991,111.37 |
| 交易性金融资产 | - | 17,166,041.11 | 20,075,204.12 | 40,446,821.92 |
| 应收票据及应收账款 | 88,537,509.79 | 74,744,474.07 | 92,449,141.35 | 61,607,249.91 |
| 其中：应收票据 | 4,372,726.43 | 1,856,477.1 | 3,401,524.55 | 2,852,457.57 |
| 应收账款 | 84,164,783.36 | 72,887,996.97 | 89,047,616.8 | 58,754,792.34 |
| 应收款项融资 | 51,727,467.45 | 52,762,999.46 | 88,901,316.75 | 65,441,439.08 |
| 预付款项 | 38,558,998.22 | 16,488,571.17 | 15,703,429.39 | 43,164,965.2 |
| 其他应收款合计 | 1,129,093.53 | 804,643.05 | 1,192,970.7 | 1,279,862.19 |
| 存货 | 115,828,473.41 | 121,266,695.44 | 120,182,793.46 | 119,784,613.63 |
| 其他流动资产 | 4,213,492 | 2,051,707.69 | 3,923,804.62 | 4,832,983.65 |
| 流动资产合计 | 742,823,347.91 | 663,569,339.53 | 695,529,906.75 | 690,549,046.95 |
| 非流动资产: | | | | |
| 长期股权投资 | 102,232,330.95 | 100,263,819.49 | 102,618,150.25 | 100,970,777.38 |
| 其他非流动金融资产 | 20,795,852.6 | 20,995,664.63 | 20,418,654.92 | 20,418,654.92 |
| 投资性房地产 | 139,828.01 | 139,828.01 | 173,042.86 | 206,257.75 |
| 固定资产 | 479,124,698.1 | 494,292,549.02 | 514,996,538.64 | 525,947,749.13 |
| 在建工程 | 258,106,907.78 | 187,941,803.22 | 163,282,602.96 | 155,148,685.46 |
| 使用权资产 | 2,157,974.24 | 2,360,284.31 | 145,237.84 | 363,094.66 |
| 无形资产 | 89,022,902.75 | 89,623,931.01 | 90,338,213.93 | 91,064,457.46 |
| 长期待摊费用 | 1,944,513.05 | 2,015,620.28 | 2,039,959.07 | 2,104,113.59 |
| 递延所得税资产 | 30,933,896.29 | 26,709,193.16 | 29,562,096.08 | 32,311,970.27 |
| 其他非流动资产 | 25,517,309.11 | 42,153,597.51 | 35,794,388.57 | 34,464,512.4 |
| 非流动资产合计 | 1,009,976,212.88 | 966,496,290.64 | 959,368,885.12 | 963,000,273.02 |
| 资产总计 | 1,752,799,560.79 | 1,630,065,630.17 | 1,654,898,791.87 | 1,653,549,319.97 |
| 流动负债: | | | | |
| 短期借款 | 331,125,424.28 | 283,571,705.92 | 314,120,470.14 | 358,056,520.01 |
| 应付票据及应付账款 | 184,061,250.14 | 164,251,409.96 | 179,065,372.31 | 158,914,160.23 |
| 其中：应付票据 | 69,174,608.32 | 75,861,553.86 | 94,335,216.4 | 51,119,316.8 |
| 应付账款 | 114,886,641.82 | 88,389,856.1 | 84,730,155.91 | 107,794,843.43 |
| 预收款项 | 12,250 | 11,000 | 11,000 | 13,394.49 |
| 合同负债 | 6,032,900.32 | 4,133,716.85 | 6,555,817.36 | 3,689,389.51 |
| 应付职工薪酬 | 18,273,988.92 | 15,270,614.59 | 11,386,230.54 | 13,885,263.72 |
| 应交税费 | 10,523,556.65 | 5,349,074.03 | 4,021,929.32 | 8,615,991.18 |
| 其他应付款合计 | 52,906,160.64 | 27,530,255.59 | 14,609,492.8 | 13,176,037.98 |
| 应付股利 | 25,200,000 | - | - | - |
| 一年内到期的非流动负债 | - | 4,504,312.5 | 9,506,584.93 | 9,506,584.93 |
| 其他流动负债 | 3,069,261.31 | 1,641,497.8 | 1,966,673.48 | 1,840,304.43 |
| 流动负债合计 | 606,004,792.26 | 506,263,587.24 | 541,243,570.88 | 567,697,646.48 |
| 非流动负债: | | | | |
| 长期借款 | 13,507,895.21 | 8,004,626.85 | - | - |
| 租赁负债 | 2,033,279.21 | 2,033,279.21 | - | - |
| 递延收益 | 7,854,192.19 | 8,209,111.69 | 8,609,853.79 | 9,010,595.89 |
| 递延所得税负债 | 21,416,858.84 | 22,385,400.23 | 22,486,267.84 | 23,691,283.72 |
| 非流动负债合计 | 44,812,225.45 | 40,632,417.98 | 31,096,121.63 | 32,701,879.61 |
| 负债合计 | 650,817,017.71 | 546,896,005.22 | 572,339,692.51 | 600,399,526.09 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 84,000,000 | 84,000,000 | 84,000,000 | 84,000,000 |
| 资本公积 | 545,358,036.78 | 533,731,272.94 | 530,468,541.13 | 528,225,562.57 |
| 减:库存股 | 18,318,193.04 | 21,911,422.12 | 21,911,422.12 | 17,930,051.12 |
| 专项储备 | 4,325,684.92 | 3,821,758.17 | 2,553,485.47 | 2,660,455.19 |
| 盈余公积 | 41,973,298.77 | 41,435,155.9 | 41,435,155.9 | 41,435,155.9 |
| 未分配利润 | 440,132,106.66 | 439,373,277.9 | 443,098,439.64 | 413,769,491.63 |
| 归属于母公司股东权益合计 | 1,097,470,934.09 | 1,080,450,042.79 | 1,079,644,200.02 | 1,052,160,614.17 |
| 少数股东权益 | 4,511,608.99 | 2,719,582.16 | 2,914,899.34 | 989,179.71 |
| 股东权益合计 | 1,101,982,543.08 | 1,083,169,624.95 | 1,082,559,099.36 | 1,053,149,793.88 |
| 负债和股东权益合计 | 1,752,799,560.79 | 1,630,065,630.17 | 1,654,898,791.87 | 1,653,549,319.97 |
| 公告日期 | 2025-10-21 | 2025-08-26 | 2025-04-22 | 2025-04-22 |
| 审计意见(境内) | | | | 标准无保留意见 |